Novogen (NASDAQ:KZIA) Stock Rating Lowered by Wall Street Zen

Novogen (NASDAQ:KZIA) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Several other brokerages also recently issued reports on KZIA. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Novogen in a report on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.00.

Novogen Price Performance

Shares of KZIA stock opened at $8.25 on Friday. Novogen has a 12-month low of $2.86 and a 12-month high of $17.40. The firm has a fifty day moving average of $6.67 and a 200-day moving average of $7.76.

Novogen (NASDAQ:KZIA) last issued its quarterly earnings data on Friday, November 7th. The company reported ($6.14) EPS for the quarter. The company had revenue of $0.59 million during the quarter.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.